Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

Magen I, Gozes I.

Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.

PMID:
24210139
2.

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I.

Neurobiol Dis. 2013 Aug;56:79-94. doi: 10.1016/j.nbd.2013.04.012. Epub 2013 Apr 28.

PMID:
23631872
3.

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

Gozes I.

Curr Pharm Des. 2011;17(31):3413-7. Review.

PMID:
21902667
4.

Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.

J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.

PMID:
24503616
5.

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Shiryaev N, Pikman R, Giladi E, Gozes I.

Curr Pharm Des. 2011;17(25):2603-12. Review.

PMID:
21728979
6.
7.

NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.

Quraishe S, Cowan CM, Mudher A.

Mol Psychiatry. 2013 Jul;18(7):834-42. doi: 10.1038/mp.2013.32. Epub 2013 Apr 16.

8.

Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.

Gozes I.

Peptides. 2011 Feb;32(2):428-31. doi: 10.1016/j.peptides.2010.10.030. Epub 2010 Nov 2. Review.

PMID:
21050875
9.

Davunetide: Peptide therapeutic in neurological disorders.

Magen I, Gozes I.

Curr Med Chem. 2014;21(23):2591-8. Review.

PMID:
24533805
10.

Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.

Morimoto BH, Fox AW, Stewart AJ, Gold M.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):483-502. doi: 10.1586/17512433.2013.827403. Epub 2013 Aug 24. Review.

PMID:
23971871
11.

NAP (davunetide) provides functional and structural neuroprotection.

Gozes I.

Curr Pharm Des. 2011;17(10):1040-4. Review.

PMID:
21524250
12.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.

J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.

13.

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I.

Neurobiol Dis. 2009 May;34(2):381-8. doi: 10.1016/j.nbd.2009.02.011. Epub 2009 Mar 2.

PMID:
19264130
14.

NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.

Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I.

Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22.

PMID:
20417241
15.

Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments.

Trojanowski JQ, Smith AB, Huryn D, Lee VM.

Expert Opin Pharmacother. 2005 May;6(5):683-6.

PMID:
15934894
16.

New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, Grigoriadis NC, Gozes I.

Autophagy. 2014;10(12):2324-32. doi: 10.4161/15548627.2014.984274.

17.

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Oz S, Ivashko-Pachima Y, Gozes I.

PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.

18.

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.

PMID:
15665412
19.

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L.

CNS Drug Rev. 2005 Winter;11(4):353-68. Review.

20.

The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules.

Yenjerla M, LaPointe NE, Lopus M, Cox C, Jordan MA, Feinstein SC, Wilson L.

J Alzheimers Dis. 2010;19(4):1377-86. doi: 10.3233/JAD-2010-1335.

Supplemental Content

Support Center